Allergan said it will begin to sell off its nearly 10 percent stake in Teva Pharmaceuticals, as the Israeli drugmaker plummets in value.
Allergan sold its generics business -- Actavis Generics -- to Teva in August 2016 for $33 billion in cash and 100 million shares of the generic drugmaker, worth around $5.3 billion at the time. Allergan was required to hold the shares for at least one year.
Read the Reuters coverage